Condition: T-Prolymphocytic Leukemia · Non-Hodgkins Lymphoma · Sponsor: Ascentage Pharma Group Inc.
The goal of this study is to evaluate the pharmacokinetics (PK), safety, and efficacy of APG-115 as a single agent or in combination with APG-2575 in patients with T-PLL and NHL.
This description comes directly from the study's public registry record.
Genevieve Frank · 301-802-3659 · genevieve.frank@ascentage.com
Jocelyn Budzynski · 301-693-6952 · jocelyn.budzynski@ascentage.com
Always discuss trial participation with your own doctor first.
| MD Anderson | Houston, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04496349